creatinine, creatine kinase (CK), CK-MB isoenzyme, cardiac troponin T (cTnT), atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP), were also performed using the blood samples taken at the end of hemodialysis. Within 2 weeks before and after sampling for these assays, we also evaluated echocardiograms and cardiothoracic ratio (CTR, [%] ) calculated by measurements on a chest X ray taken after a routine hemodialysis treatment.
Seventeen outpatients (11 men and 6 women; mean age, 60.2 ± 14.7 years) with neither coronary heart disease nor renal dysfunction as determined by serial clinical evaluations such as biochemical tests, electrocardiography, and echocardiography were enrolled as control subjects. The values of hemoglobin, albumin, creatinine, H-FABP, myoglobin, CK, CK-MB, and cTnT were measured and chest X-ray photography and echocardiography were also performed.
Measurement of Biochemical Cardiac Markers
The serum H-FABP concentration was measured with a commercially available two-step direct sandwich-ELISA kit (Markit-M H-FABP, Dainippon Pharmaceutical Co, Osaka, Japan). The accuracy, precision and reproducibility of this kit have been described previously. 9 The serum Ratio of heart-type fatty acid-binding protein to myoglobin (F/M) in the control subjects (n=17) and hemodialysis patients (n=21). The value of F/M at the end of hemodialysis was significantly higher than that in the control patients. Using a cutoff point of mean + 2SD of the F/M level in the control subjects (value: 0.147), the hemodialysis patients were divided into 2 groups, a high F/M group (n=10) and a low F/M group (n=11). *p<0.01. concentration of myoglobin mass was measured with a radioimmunoassay kit (Myoglobin-kit [Daiichi] III, Daiichi Radioisotope Co, Tokyo, Japan). Total CK activity was measured using a standard colorimetric assay and serum CK-MB activity was determined using an immuno-inhibition assay kit (Merck Auto CK-MB, Kanto Kagaku Co, Tokyo, Japan). The serum cTnT concentration was measured using a second-generation cTnT sandwich electrochemiluminescence immunoassay kit (ECLusys Troponin T III STAT, Roche Diagnostics, Tokyo, Japan). Plasma ANP and BNP concentrations were measured using each specific sandwich-type immunoradiometric assay kit (Shionoria, Shionogi & Co, Osaka, Japan). The upper limits of the normal reference ranges of ANP and BNP are 40 pg/ml and 20 pg/ml, respectively.
Echocardiography
Echocardiographic determination of the left ventricular ejection fraction (EF), left ventricular end-diastolic dimension (LVDd), left atrial dimension (LAD) and the inferior vena cava (IVC) were recorded and evaluated by 2 experienced echocardiographers. Left ventricular mass index (LVMI) was calculated by Devereux's formula. 10 
Statistical Analysis
All numeric variables were expressed as mean ± SD. The difference between 2 independent variables was analyzed by the Mann-Whitney U test. The difference between 2 paired variables was analyzed by the Wilcoxon signed rank test. Group statistical comparisons were assessed by oneway analysis of variance and the chi-square test. A p-value of <0.05 was considered statistically significant.
Results
The F/M value in the hemodialysis patients before hemodialysis was significantly higher than that in the control subjects (0.185±0.016 vs 0.101±0.023, p<0.01). After hemodialysis, the F/M value in the hemodialysis patients was significantly decreased (0.185±0.016 vs 0.157±0.010, p<0.01) but was still higher than that in the controls (Fig 1) . Using a cutoff point of mean + 2SD of the F/M value in the controls (value: 0.147), the hemodialysis patients were divided into 2 groups, a high F/M group and a low F/M group. As shown in Table 1 , there were no inter-group differences in age, gender or the values of CK and CK-MB. Regardless of F/M value, the hemodialysis patients had a significantly lower concentration of hemoglobin and higher concentrations of H-FABP, myoglobin, cTnT and creatinine than did the control subjects. The plasma concentrations of ANP and BNP at the end of hemodialysis in the high F/M group were higher than those in the low F/M group. The mean concentration of ANP in the low F/M group was almost the upper limit of the normal range. The values of LVDd, LAD, LVMI, and CTR in the high F/M group were also higher than those in the low F/M group, and the mean values of those in the low F/M group were almost the same as those in the control subjects.
Discussion
Both H-FABP and myoglobin are present not only in the myocardium but also in skeletal muscle. The H-FABP content in cardiac muscle is higher than that in skeletal muscle, whereas the myoglobin content in cardiac muscle is lower than that in skeletal muscle. 7, 11 Therefore, there is a sharp contrast in the content of each protein in the heart and skeletal muscle. The molecular weight of H-FABP is 15 kDa and that of myoglobin is 18 kDa, therefore it is expected that the sieving effect of hemodialysis dialysers on H-FABP and myoglobin would be similar because these proteins have almost the same molecular weights. Van Nieuwenhoven et al reported that the ratio of the concentrations of myoglobin over H-FABP allowed discrimination of myocardial and skeletal muscle injuries. 7 In addition, the concentration of H-FABP has been proposed as an early marker for not only acute myocardial infarction, 1,2 but also detection and evaluation of myocardial damage in patients with heart failure. 3 Taking these points into consideration, we previously examined and showed that the value of F/M at the end of hemodialysis, but not the concentration of H-FABP or that of myoglobin alone, could be a useful marker of cardiac damage and volume overload in hemodialysis patients. 8 In the present study, the F/M value in the hemodialysis patients was significantly decreased after hemodialysis. Furthermore, we showed that F/M value at the end of hemodialysis could be a useful marker of cardiac involvement regardless of renal dysfunction.
ANP has been reported as an indicator of volume status in hemodialysis patients. 12 Echocardiographic indices, such as LVDd and LAD, and CTR are also volume markers of the cardiac system. Furthermore, left ventricular hypertrophy frequently occurs in hemodialysis patients and is a strong predictor of death. 13 It has also been reported that BNP is related to left ventricular mass and function and is a predictor of mortality in dialysis patients. 14 In the present study, the concentration of ANP in the high F/M group was higher than that in the low F/M group. It has been reported that plasma ANP concentrations are still routinely elevated after hemodialysis even when patients are determined to be clinically at their dry weight. 15 Interestingly, the mean concentration of ANP in the low F/M group was almost the upper limit of the normal range. In a different investigation, we have also confirmed that the F/M value is reduced with improvement of cardiac damage in some hemodialysis patients with heart failure (unpublished data, 2002). The F/M value may primarily reflect the degree of extracellular volume, which means the degree of heart failure, but not the ischemic change of the heart, which is perhaps irreversible. In addition, the mean values of LVDd, LAD, LVMI, and CTR in the low F/M group were almost the same as those in the control patients. These findings indicate that the value of F/M could be evaluated by the absolute value in patients with or without renal dysfunction and that the value of 0.147 for the F/M could be useful for determining the cutoff level of cardiac involvement.
Both H-FABP and myoglobin appear in substantial quantities in serum within 2-3 h of the onset of cardiac damage, whereas other cardiac proteins such as CK-MB and cTnT take at least 4 h to appear in serum. 2, 16, 17 It is possible that the value of F/M varies more rapidly depending on the condition of cardiac damage. Therefore, it is thought that F/M is more sensitive and more valuable for assessing cardiac damage during treatment of heart failure and hypertension in patients with and without renal dysfunction.
One limitation of this study is the small number of subjects enrolled, so it is important to substantiate our conclusion by studies with more patients. Because we did not perform other invasive and non-invasive examinations such as cardiac catheterization and cardiac scintigraphy in the present study, further studies using detailed examinations are also needed to evaluate the cardiac damage. Assessment of F/M might be useful for risk stratification and for guiding treatment of observational or interventional studies in both patients with normal renal function and hemodialysis patients. Therefore, it is necessary to prospectively evaluate whether a change in the F/M value reflects the condition of the cardiac damage and predicts long-term outcomes.
In summary, the F/M value in hemodialysis patients was significantly higher than that in the control subjects. Using a cutoff point of mean + 2SD in the control subjects, the high F/M group at the end of hemodialysis showed significantly higher values of ANP, BNP, LVDd, LAD, LVMI, and CTR compared with those in the control subjects and/or low F/M group. The F/M value can be evaluated by the absolute value regardless of renal dysfunction, and the value of 0.147 might be useful for determining the cutoff level of cardiac involvement.
